Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,841 across all filing types
Latest filing 2025-11-03 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
关于回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the progress of the company's share repurchase program. It details the board resolutions approving the share buyback, the funding sources, the adjusted price limits following dividend distributions, and the cumulative shares repurchased to date. It references compliance with regulatory rules on share repurchases and provides specific transaction details such as number of shares, prices, and total amount spent. The document does not contain full financial statements or comprehensive financial analysis but focuses solely on the share repurchase activity and its regulatory compliance. Therefore, it fits the category of a Transaction in Own Shares (POS) filing, which covers reports of the company buying back its own shares.
2025-11-03 Chinese
关于对下属公司担保的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 普洛药业股份有限公司 regarding the progress of guarantees provided to its subsidiaries. It details the guarantee contract, the amount, the parties involved, and the board's opinion on the guarantee. The document is relatively short (2010 characters) and focuses on a specific financial guarantee update rather than a full financial report or audit. It does not contain comprehensive financial statements or detailed financial analysis. It is an announcement about a financing-related activity (providing guarantees for loans), which fits best under Capital/Financing Update (CAP).
2025-10-31 Chinese
关于获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from a company about receiving a drug registration certificate from a national regulatory authority. It details the product name, specifications, approval, and potential impact on the company. There is no financial data, no mention of a report being attached or published, and it is not a financial or management report. It is a regulatory announcement about a product approval, which fits best under Regulatory Filings (RNS) as it does not fit other specific categories like Annual Report, Earnings Release, or Capital Update.
2025-10-31 Chinese
关于公司产品拟中选第十一批全国药品集中采购的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about its product being selected in a national centralized drug procurement batch. It includes details about the product, pricing, procurement period, and potential impact on the company. The document is short (919 characters) and does not contain financial statements or detailed financial data. It is an announcement of a business event related to product procurement and its expected impact, not a financial report or regulatory filing. It does not fit into categories like Annual Report, Earnings Release, or Capital Update. It is a regulatory announcement about a business development, best classified under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2025-10-28 Chinese
第九届董事会第十六次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a board meeting resolution announcement from 普洛药业股份有限公司 regarding the approval of the 2025 third quarter report. It includes details about the meeting date, attendance, and voting results. The document itself does not contain the actual financial data or the full quarterly report but only announces the board's approval of the report. The document length is very short (393 characters), indicating it is an announcement rather than the full report. Therefore, it fits best under the category of Regulatory Filings (RNS) as a general announcement of board decisions and report approval without substantive financial content.
2025-10-21 Chinese
2025年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2025 年第三季度报告" which translates to "2025 Third Quarter Report." It contains detailed financial data including income, net profit, cash flow, assets, liabilities, and shareholder information for the third quarter of 2025. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year indicates this is an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial data rather than just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). 9M 2025
2025-10-21 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.